Drug Database
Back to search

Netherlands· NL-5f3b61fbeb3b

Neostigminemethylsulfaat CF 0,5 mg/ml, injectievloeistof

A neostigmine product containing neostigmine methylsulfaat, registered in Netherlands by Centrafarm B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC N07AA01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNeostigminemethylsulfaat CF 0,5 mg/ml…ATCN07AA01REGISTER NO.NL-5f3b61fbeb3bPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about neostigmine methylsulfaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Neostigmine is registered in 10 of 19 countries.

Countries holding a registration under ATC N07AA01 (neostigmine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search neostigmine products by name

Neostigmine · ATC N07AA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NEOSTIGMINE METHYLSULFAAT
Manufacturer
Centrafarm B.V.
Country
Netherlands (NL)
ATC code
N07AA01
ATC class
Neostigmine
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    50842

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

68 interactions on record for neostigmine.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check neostigmine against other medicinesHow interaction checks work

Neostigmine · interactions on record

68 records

  • 6 severe
  • 62 moderate

Most severe, free to view

  • SiponimodL04AA42severe
  • SiponimodL04AE03severe
  • BupropionN06AX12severe
  • BupropionN07BA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Neostigmine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All neostigmine products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Neostig, Normastigmin
  • Cyprus · Neostigmine Cooper
  • Czechia · Syntostigmin
  • Germany · Neostig, Neostigmin Panpharma
  • Spain · Neostigmina Braun
  • France · Néostigmine Renaudin, Prostigmine
  • United Kingdom (Northern Ireland) · Neostigmine Methylsulfate Bp Hameln Pharma
  • Greece · Neostigmine Cooper
  • Croatia · Neostigmin Panpharma
  • Hungary · Neostigmine Kalceks, Stigmosan
  • Latvia · Neostigmine Kalceks
  • Poland · Polstigminum
  • Portugal · Neostigmina Braun
  • Romania · Miostin
  • Sweden · Neostigmin Unimedic Pharma Ab
  • Slovakia · Syntostigmin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b8f02a61-dfb7-4aaa-8e27-558896c32fad
GET /v1/drugs/b8f02a61-dfb7-4aaa-8e27-558896c32fad?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": null,
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h50842_smpc.pdf",
  "strength": null,
  "atc_label": "Neostigmine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg50842",
  "excipients": [
    "BENZYLALCOHOL (E 1519)",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "NEOSTIGMINE METHYLSULFAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h50842.pdf",
  "authorised_at": "1992/12/31",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "50842",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about neostigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console